Atossa Therapeutics, Inc. (ATOS)
$
0.76
-0.05 (-6.58%)
Key metrics
Financial statements
Free cash flow per share
-0.1727
Market cap
107.4 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
12.6717
Income quality
0.8462
Average inventory
0
ROE
-0.3626
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, specializes in the discovery and development of medicines targeting oncology and infectious diseases. The company's lead program, Endoxifen, which is an active metabolite of tamoxifen, is currently undergoing Phase II clinical trials aimed at treating and preventing breast cancer. Additionally, Atossa is advancing its development of AT-H201, an inhalation therapy designed to enhance lung function in severely ill and hospitalized COVID-19 patients, and AT-301, a proprietary drug candidate for nasal administration in those diagnosed with COVID-19. Moreover, the company is pursuing immunotherapy and chimeric antigen receptor therapy programs targeting breast cancer treatment. A notable collaboration exists with the Dana-Farber Cancer Institute, Inc. to foster research into cytokine-coated nanoparticles for breast cancer therapy. In its financial pursuits, the company earned an interest income of $4,050,000.00 showcasing its financial investments. The income before tax ratio is 0.00 reflecting the pre-tax margin, while the net total of other income and expenses amounts to $2,117,000.00 indicating non-core financial activities. The operating expenses total $27,604,000.00 encompassing various operational costs incurred by the company, and its diluted EPS stands at -$0.20 accounting for potential share dilution. Turning to Atossa’s market positioning, the stock is affordable at $0.76 making it suitable for budget-conscious investors. The stock has an average trading volume of 667,972.00 indicating moderate liquidity, which may appeal to a range of investors. With a market capitalization of $98,233,784.00 the company is classified as a small-cap player, providing unique investment opportunities. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, which is driving innovation and growth within the biopharmaceutical space. This combination of financial performance and strategic focus positions Atossa Therapeutics, Inc. as a noteworthy entity for consideration among potential investors.
Is Atossa Therapeutics, Inc. (ATOS) a good investment?
Investing in Atossa Therapeutics, Inc. (ATOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Atossa Therapeutics, Inc. (ATOS)'s stock forecast?
Analysts predict Atossa Therapeutics, Inc. stock to fluctuate between $0.55 (low) and $1.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atossa Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Atossa Therapeutics, Inc.'s market cap is $98,233,784, based on 129,169,999 outstanding shares.
How does Atossa Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Atossa Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Atossa Therapeutics, Inc. (ATOS) stock?
To buy Atossa Therapeutics, Inc. (ATOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Atossa Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Atossa Therapeutics, Inc. stock ever split?
Atossa Therapeutics, Inc.'s last stock split was 1:12 on 2018-04-20.
How did Atossa Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.20 | Growth: -16.67%.
Where can I find Atossa Therapeutics, Inc.'s investor relations reports?
Visit https://www.atossatherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atossa Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Atossa Therapeutics, Inc. stock?
All-time high: $9.80 (2021-06-25) | All-time low: $0.50 (2022-12-28).
What are the key trends affecting Atossa Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
10 days ago
SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Dr. Steven Quay, CEO of Atossa Therapeutics.
zacks.com
15 days ago
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
prnewswire.com
16 days ago
Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE , May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. Key Findings: Primary feasibility goal surpassed – 95 percent of participants (19/20) completed at least 75 percent of planned dosing, far exceeding the predefined 75 percent threshold.
prnewswire.com
17 days ago
Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE , May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments. First Quarter 2025 Highlights: Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa announced plans to target metastatic breast cancer as its lead program for (Z)-endoxifen.
globenewswire.com
a month ago
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations.
globenewswire.com
a month ago
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition, to significantly reduce interval breast cancer in women identified as high-risk through advanced mammographic screening techniques. The proposed SMART 2.0 study was presented at the American Association for Cancer Research (AACR) Annual Meeting and represents a future research program and potential partnership opportunity to advance this critical initiative for women at high risk of breast cancer.
globenewswire.com
a month ago
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
prnewswire.com
2 months ago
CAMBRIDGE, Mass. , April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS).
zacks.com
2 months ago
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com
2 months ago
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.
See all news
